{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:44:45Z","timestamp":1773798285431,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01296-8","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T06:39:07Z","timestamp":1750142347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and\/or Refractory Myeloma (RRMM)"],"prefix":"10.1038","volume":"15","author":[{"given":"Chandramouli","family":"Nagarajan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9339-3362","authenticated-orcid":false,"given":"Wei-Ying","family":"Jen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7392-0655","authenticated-orcid":false,"given":"Melissa","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8881-3537","authenticated-orcid":false,"given":"Sanjay","family":"De Mel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinnie","family":"Soekojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2302-3825","authenticated-orcid":false,"given":"Sung Soo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9039-3474","authenticated-orcid":false,"given":"Yunxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogesh","family":"Pokharkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi Ning","family":"Tham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur Shahidah Binte","family":"Hashim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah M.","family":"Burkill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Durie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2578-8335","authenticated-orcid":false,"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"1296_CR1","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016;43:676\u201381.","journal-title":"Semin Oncol"},{"key":"1296_CR2","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N. Engl J Med. 2016;375:754\u201366.","journal-title":"N. Engl J Med"},{"key":"1296_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Delimpasis S, Beksac M, Katodritou E, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:801\u201312.","journal-title":"Lancet Oncol"},{"key":"1296_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41375-020-0809-x","volume":"35","author":"T Hideshima","year":"2021","unstructured":"Hideshima T, Ogiya D, Liu J, Harada T, Kurata K, Bae J, et al. Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways. Leukemia. 2021;35:177\u201388.","journal-title":"Leukemia"},{"key":"1296_CR5","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1182\/blood.2020006200","volume":"136","author":"M Naeimi Kararoudi","year":"2020","unstructured":"Naeimi Kararoudi M, Nagai Y, Elmas E, Fernandes Pereira MDS, Abbas Ali S, Imus PH, et al. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood. 2020;136:2416\u201327.","journal-title":"Blood"},{"key":"1296_CR6","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N. Engl J Med. 2016;375:1319\u201331.","journal-title":"N. Engl J Med"},{"key":"1296_CR7","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","volume":"130","author":"A Chari","year":"2017","unstructured":"Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma. Blood. 2017;130:974\u201381.","journal-title":"Blood"},{"key":"1296_CR8","doi-asserted-by":"publisher","first-page":"e213497","DOI":"10.1001\/jamanetworkopen.2021.3497","volume":"4","author":"HM Blommestein","year":"2021","unstructured":"Blommestein HM, Franken MG, van Beurden-Tan CHY, Blijlevens NMA, Huijgens PC, et al. Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma. JAMA Netw Open. 2021;4:e213497\u2013e.","journal-title":"JAMA Netw Open"},{"key":"1296_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/14737167.2022.2017285","volume":"22","author":"XY Wong","year":"2022","unstructured":"Wong XY, Chng WJ, Aziz MIA, Ng K. Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and\/or refractory multiple myeloma. Expert Rev Pharmacoecon Outcomes Res. 2022;22:207\u201315.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1296_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","volume":"21","author":"D Weber","year":"2003","unstructured":"Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16\u20139.","journal-title":"J Clin Oncol"},{"key":"1296_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","volume":"24","author":"SV Rajkumar","year":"2006","unstructured":"Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431\u20136.","journal-title":"J Clin Oncol"},{"key":"1296_CR12","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","volume":"26","author":"SV Rajkumar","year":"2008","unstructured":"Rajkumar SV, Rosi\u00f1ol L, Hussein M, Catalano J, Jedregezak J, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008;26:2171\u20137.","journal-title":"J Clin Oncol"},{"key":"1296_CR13","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1200\/EDBK_200869","volume":"38","author":"R Fonseca","year":"2018","unstructured":"Fonseca R, Hinkel J. Value and Cost of Myeloma Therapy\u2014We Can Afford It. Am Soc Clin Oncol Educ Book. 2018;38:647\u201355.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1296_CR14","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s00277-012-1506-2","volume":"91","author":"SY Wu","year":"2012","unstructured":"Wu SY, Yeh YM, Chen YP, Su WC, Chen TY. Low incidence of thromboembolism in relapsed\/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan. Ann Hematol. 2012;91:1773\u20138.","journal-title":"Ann Hematol"},{"key":"1296_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.thromres.2012.11.014","volume":"131","author":"A Kato","year":"2013","unstructured":"Kato A, Takano H, Ichikawa A, Koshino I, Igarashi A, Hattori K, et al. A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin. Thromb Res. 2013;131:140\u20134.","journal-title":"Thromb Res"},{"key":"1296_CR16","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"1296_CR17","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e46.","journal-title":"Lancet Oncol"},{"key":"1296_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","volume":"396","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos M, Quach H, Mateos M-V, Landgren O, Leleu X, Siegel D, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396:186\u201397.","journal-title":"Lancet"},{"key":"1296_CR19","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","volume":"387","author":"S Lonial","year":"2016","unstructured":"Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387:1551\u201360.","journal-title":"Lancet"},{"key":"1296_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00957-w","volume":"13","author":"C Charalampous","year":"2023","unstructured":"Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, et al. Comparison of daratumumab-based regimens as second-line therapy in relapsed\/refractory multiple myeloma. Blood Cancer J. 2023;13:183.","journal-title":"Blood Cancer J"},{"key":"1296_CR21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1182\/bloodadvances.2023010579","volume":"8","author":"A Spencer","year":"2024","unstructured":"Spencer A, Moreau P, Mateos M-V, Goldschmidt H, Suzuki K, Levin M-D, et al. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX. Blood Adv. 2024;8:388\u201398.","journal-title":"Blood Adv"},{"key":"1296_CR22","doi-asserted-by":"publisher","first-page":"10007","DOI":"10.1182\/blood-2022-165109","volume":"140","author":"S Zhao","year":"2022","unstructured":"Zhao S, Wellard C, McQuilten Z, Moore EM, Wood EM, Spencer A, et al. Real World Comparison of Treatment Outcomes for Myeloma in Elderly Transplant-Ineligible Population with RVD, RD and VCD in Frontline Setting: Results from MRDR Australia and New Zealand. Blood. 2022;140:10007\u20138.","journal-title":"Blood"},{"key":"1296_CR23","doi-asserted-by":"publisher","first-page":"5518","DOI":"10.1182\/blood-2019-124256","volume":"134","author":"N Aoki","year":"2019","unstructured":"Aoki N, Moore EM, Wood EM, McQuilten Z, Wellard C, Spencer A. Real-World Treatment Patterns and Clinical Outcomes in Multiple Myeloma in the Asia-Pacific Region: Methodology and Preliminary Results of the Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR). Blood. 2019;134:5518.","journal-title":"Blood"},{"key":"1296_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0071-x","volume":"8","author":"K Suzuki","year":"2019","unstructured":"Suzuki K, Dimopoulos MA, Takezako N, Okamoto S, Shinagawa A, Matsumoto M, et al. Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study. Blood Cancer J. 2019;8:41.","journal-title":"Blood Cancer J"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01296-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01296-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01296-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T06:39:07Z","timestamp":1750142347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01296-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1296"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01296-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"21 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All patients provided informed consent before trial entry. The trial was approved by institutional IRBs of all participating centres. The trial was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"109"}}